SOURCES SOUGHT
88 -- Generation of Transgenic Mouse with Human Chimeric Transferrin Receptor
- Notice Date
- 4/9/2020 1:45:00 PM
- Notice Type
- Sources Sought
- NAICS
- 112990
— All Other Animal Production
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- NINDS-20-005984
- Response Due
- 4/23/2020 11:00:00 AM
- Archive Date
- 05/08/2020
- Point of Contact
- Michelle Cecilia, Phone: 3018277199, Valerie Whipple, Phone: 3018275218
- E-Mail Address
-
michellececilia.cecilia@nih.gov, Valerie.Whipple@nih.gov
(michellececilia.cecilia@nih.gov, Valerie.Whipple@nih.gov)
- Description
- Federal Business Opportunities (Beta.sam.gov) SOURCES SOUGHT NOTICE� 1.�� �Solicitation Number:�� � NINDS-20-005984 Title: Generation of transgenic mouse with human chimeric transferrin receptor 2.�� � NAICS Code: �112990 � All other animal production 3.�� �Description: � This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. �It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. �Responses will not be considered as proposals or quotes. �No award will be made as a result of this notice. �The Government will NOT be responsible for any costs incurred by the respondents to this notice. �This notice is strictly for research and information purposes only. Background: The Brain MRI Molecular Contrast Unit (BMCCU) under Dr. Alan Koretsky in NINDS is developing a novel class of brain MRI contrast agents which will provide for improved contrast of specific brain pathologies. �As part of this endevour, the ability to translate into humans is paramount. �There are distinct amino acid level differences between the mouse and human transferrin receptor, which will be utilized as the targeting domain for delivery into the brain. �We require the production of a novel transgenic mouse model possessing human protein sequence embedded in the endogenous mouse transferrin receptor to allow for binding and uptake while not interfering with the native function of the receptor in mouse biology. Purpose and Objectives: The NNU�s iLAST clinical trial, which was recently IRB approved, is a feasibility study aims to explore new techniques for optimizing the use of electroconvulsive therapy (ECT) to treat depression. In conjunction with ECT treatments, several neuroimaging techniques including EEG will be used to collect data on the cortical changes associated with the iLAST treatment.� The NNU lab has previously ordered custom EEG caps from Brain Vision LLC for use during the iLAST clinical trial. The new acquisition described is an amplifier which is compatible with the NNU lab�s current EEG caps and would allow for the collection of high-quality EEG data for analysis. The amplifier system comes with associated accessories required for use, as described in the quote attached, and the adaptors are required to connect the amplifier to our passive EEG caps. Purchase Description:� The Government is looking to generate a novel human-mouse transferrin receptor transgenic mouse model with the salient characteristics listed below.� 4.�� �Salient characteristics� A novel human-mouse chimeric transferrin receptor transgenic mouse model as follows:� i)�� �The mouse endogenous transferrin receptor apical domain (amino acids 199-381) will be replaced with the human transferrin receptor apical domain (amino acids 196-378). ii)�� �The mouse will be designed such that the endogenous intron/exons will be utilized and not a cDNA cassette to preserve intronic signaling which may not be fully elucidated and lead to potential transcription/translation error. iii)�� �The mouse will be engineered using CRISPR/Cas9 methodology using genomic sequence for development of the targeting construct. iv)�� �The final construct will be introduced into ES cells to establish validated knockin cells for introduction into mice. �The ES cell clones will be karyotyped to ensure correct insertion within the locus. v)�� �Heterozygous mice will be generated from the ES cell clones for delivery. Anticipated Delivery: Delivery shall occur within 34-40 weeks after receipt of order based on typical model generation timelines.� Gurantee of deliverables: A minimum of two heterozygous knockin chimeric mice will be delivered, healthy, and capable of breeding to establish a sustained animal colony. Other important considerations: N/A Capability statement /information sought: Respondents must provide clear and convincing documentation of their capability of providing the products specified in this notice. Also, information must be provided in sufficient details of the respondents� (a) staff expertise, including their availability, experience, formal and other training; (b) current in-house capability to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and other management capability; and (e) examples of prior completed Government contracts, references, and other related information. The respondent must also provide their �DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. Finally, respondents are also encouraged to provide a general overview of the respondent�s opinions about the difficulty and/or feasibility of the potential requirement, and any other information regarding innovative ideas or concepts that may be applicable.� Submission Instructions: One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2� x 11� paper size, with 1� top, bottom, left and right margins, and with single or double spacing. The information submitted must be must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. �A cover page and an executive summary may be included but is not required.� The response is limited to ten (10) page limit. �The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents� technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. �Facsimile responses are NOT accepted. The response must be submitted to Michelle Cecilia, Contract Specialist, NIH/NIDA/NIMH at michellececilia.cecilia@nih.gov and Contracting Officer at valerie.whipple@nih.gov . The response must be received on or before April 23, 2020 at 2:00 p.m. Eastern Time. �Disclaimer and Important Notes: �This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work.� Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).� �
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/44dffbe05882472dbbf048f766065ed3/view)
- Place of Performance
- Address: Bethesda, MD 20892, USA
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN05617019-F 20200411/200409230154 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |